Ozaslan E.Aksoy A.Gumusay O.Arpaci E.Berk V.2024-08-042024-08-0420151513-7368https://doi.org/10.7314/APJCP.2015.16.6.2581https://hdl.handle.net/11616/91694[No abstract available]eninfo:eu-repo/semantics/openAccessantineoplastic agentpaclitaxeladultagedfemalefollow uphumanmalemelanomamiddle agedmortalityprognosissalvage therapysurvival rateAdultAgedAntineoplastic Agents, PhytogenicFemaleFollow-Up StudiesHumansMaleMelanomaMiddle AgedPaclitaxelPrognosisSalvage TherapySurvival RateSalvage chemotherapy with weekly paclitaxel for metastatic melanomaLetter166258125812582480010.7314/APJCP.2015.16.6.25812-s2.0-84929223642Q3